Search

for
Search:

Sort by

Research

30-60 / 1000+ results

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

October 2025 in “Dermatology and Therapy”

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Phase I/IIa Clinical Trial for the Treatment of Androgenetic Alopecia Using Intradermal Injections of Cultured Autologous Dermal Sheath Cup Cells

research 281 Phase I/IIa clinical trial for the treatment of androgenetic alopecia using intradermal injections of cultured autologous dermal sheath cup cells

September 2017 in “Journal of Investigative Dermatology”

Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.

research Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men

29 citations , July 2009 in “Journal of Dermatology”

5% minoxidil works better for hair growth than 1% minoxidil.

A Phase IIA Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Selective Androgen Receptor Modulator (SARM), MK-0773 in Female Participants with Sarcopenia

research A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia

211 citations , May 2013 in “Journal of Nutrition Health & Aging”

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The Allegro Phase 2b/3 Randomized Clinical Trial

research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial

4 citations , October 2024 in “American Journal of Clinical Dermatology”

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

research The Hair Growth-Promoting Effect ofRumex japonicusHoutt. Extract

8 citations , January 2016 in “Evidence-based Complementary and Alternative Medicine”

Rumex japonicus extract may promote hair growth more effectively than Minoxidil.

research 185 Infrared and high frequency ultrasound imaging of skin lesions in atopic dermatitis and psoriasis vulgaris

September 2019 in “Journal of Investigative Dermatology”

Sandalore®, a synthetic scent, reduced hair loss and improved hair growth in women with telogen effluvium.

research Hair growth control by innate immunocytes: Perifollicular macrophages revisited

21 citations , March 2019 in “Experimental Dermatology”

Immune cells around hair follicles help control hair growth and could be targets for treating hair disorders.

research Industry update: the latest developments in the field of therapeutic delivery, July 2018

1 citations , November 2018 in “Therapeutic Delivery”

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

research The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models

85 citations , January 1996 in “International Journal of Cancer”

AS101 reduces hair loss from chemotherapy.

Minoxidil and Rosemary Essential Oil: Proposal for a Topical Solution for Androgenetic Alopecia

research Minoxidil e óleo essencial de alecrim: proposta de solução tópica para alopecia androgenética

May 2026 in “Revista Ensaios Pioneiros”

A topical solution with minoxidil and rosemary oil may help treat hair loss.

research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)

157 citations , December 2015 in “Journal of the American Academy of Dermatology”

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

$Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib$

research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib

6 citations , April 2021 in “Frontiers in Immunology”

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

research Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials

February 2010 in “Journal of The American Academy of Dermatology”

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia: Results from a Phase 1 Trial

research Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 Trial

2 citations , April 2016 in “Journal of The American Academy of Dermatology”

Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.

Sublingual Minoxidil for the Treatment of Male and Female Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase 1B Clinical Trial

research Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial

5 citations , August 2021 in “Journal of The European Academy of Dermatology and Venereology”

Sublingual minoxidil safely promotes hair growth.

Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

November 2024 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Phase I Clinical Trial: Evaluating the Efficacy, Safety, and Patient Satisfaction of Platelet-Rich Plasma Injections and Microneedling for Androgenetic Alopecia Treatment

research Phase I Clinical Trial: Evaluating the Efficacy, Safety, and Patient Satisfaction of Platelet‐Rich Plasma (PRP) Injections and Microneedling for Androgenetic Alopecia Treatment

September 2025 in “Journal of Cosmetic Dermatology”

PRP and microneedling both effectively improve hair growth and thickness for treating hair loss.

research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).

2 citations , May 2011 in “Journal of Clinical Oncology”

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

February 2026 in “Journal of Dermatological Treatment”

CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

2 citations , November 2025 in “Journal of the American Academy of Dermatology”

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes

research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

93 citations , May 2010 in “European Journal of Cancer”

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe and well-tolerated for treating hair loss in men.

research Faculty Opinions recommendation of Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.

September 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”

research An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)

2 citations , March 2009 in “Journal of Clinical Dermatology”

Topical 5% minoxidil is safe and effective for treating hair loss in Korean men.

research Bicalutamide 25 mg associated with minoxidil 1 mg versus minoxidil 1 mg for female-pattern hair loss: A randomized double-blind clinical trial

January 2025 in “JAAD International”

Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.

← Previous page Next page →

Search

for
Search:

Research

research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

research 281 Phase I/IIa clinical trial for the treatment of androgenetic alopecia using intradermal injections of cultured autologous dermal sheath cup cells

research Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men

research A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia

research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial

research The Hair Growth-Promoting Effect ofRumex japonicusHoutt. Extract

research 185 Infrared and high frequency ultrasound imaging of skin lesions in atopic dermatitis and psoriasis vulgaris

research Hair growth control by innate immunocytes: Perifollicular macrophages revisited

research Industry update: the latest developments in the field of therapeutic delivery, July 2018

research The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models

research Minoxidil e óleo essencial de alecrim: proposta de solução tópica para alopecia androgenética

research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)

research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib

research Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials

research Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 Trial

research Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial

research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

research Phase I Clinical Trial: Evaluating the Efficacy, Safety, and Patient Satisfaction of Platelet‐Rich Plasma (PRP) Injections and Microneedling for Androgenetic Alopecia Treatment

research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

research Faculty Opinions recommendation of Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.

research An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)

research Platelet-Rich Plasma (PRP) in Dermatology: Cellular and Molecular Mechanisms of Action

research Adipose derived stem cell based therapies or male/female pattern hair loss

research Adipose derived stem cell based therapies or male/female pattern hair loss

research Bicalutamide 25 mg associated with minoxidil 1 mg versus minoxidil 1 mg for female-pattern hair loss: A randomized double-blind clinical trial